Cellectis SA
PAR:ALCLS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Cellectis SA
Stock-Based Compensation
Cellectis SA
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cellectis SA
PAR:ALCLS
|
Stock-Based Compensation
$6.1m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-16%
|
|
|
Valneva SE
PAR:VLA
|
Stock-Based Compensation
€9.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
40%
|
CAGR 10-Years
56%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Inventiva SA
PAR:IVA
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Stock-Based Compensation
$5.4m
|
CAGR 3-Years
2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-7%
|
|
|
Abivax SA
PAR:ABVX
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Cellectis SA
Glance View
Cellectis SA engages as a biopharmaceutical company that harnesses the immune system to target and eradicate cancer cells. The company is headquartered in Paris, Ile-De-France and currently employs 345 full-time employees. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.
See Also
What is Cellectis SA's Stock-Based Compensation?
Stock-Based Compensation
6.1m
USD
Based on the financial report for Dec 31, 2025, Cellectis SA's Stock-Based Compensation amounts to 6.1m USD.
What is Cellectis SA's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
-16%
Over the last year, the Stock-Based Compensation growth was 93%. The average annual Stock-Based Compensation growth rates for Cellectis SA have been -16% over the past three years , -18% over the past five years , and -16% over the past ten years .
